# P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain

> **NCT00390845** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Pain, Neuropathic

## Interventions

- **DRUG:** SB681323
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00390845
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-30
- **Primary completion:** 2008-08-11
- **Final completion:** 2008-08-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390845, "P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00390845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*